ANAHEIM, Calif., July 27 /PRNewswire/ -- Xoft, Inc. today announced that it has expanded the treatment capabilities of the Axxent® Electronic Brachytherapy, eBx(TM), System with the launch of a multi-center skin cancer trial to further prove the safety and feasibility for the treatment of non-melanoma skin cancers here at the 51st Annual American Association of Physicists in Medicine (AAPM) Meeting. The Company also announced that the first skin cancer patients were recently treated using the FDA-cleared Axxent System, which has been available for the treatment of early stage breast cancer since 2005 and endometrial cancer since 2008.
